Milnacipran hydrochloride: A Selective Serotonin Noradrenaline Reuptake Inhibitor (SNRI)
Milnacipran hydrochloride is a selective serotonin noradrenaline reuptake inhibitor (SNRI) which acts by inhibiting noradrenaline (norepinephrine) and serotonin (5-hydroxytrytamine; 5-HT) reuptake at presynaptic sites. Milnacipran has unique characteristics that distinguish it from the other SNRIs, venlafaxine [
V0110] and duloxetine [
D4223], such as inhibition of noradrenaline reuptake with approximately 3-fold higher potency
in vitro than serotonin. Milnacipran has no significantt affinity for other neurotransmitter receptors, such as serotonergic, α- and β-adrenergic, muscarinic, histamine, dopamine, opioid, benzodiazepine, and γ-aminobutyric acid (GABA) receptors
in vitro. Milnacipran does not inhibit the activity of human monoamine oxidases (MAO-A and MAO-B) or acetylcholinesterase. (The product is for research purpose only.)